Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.
This overview is generated using artificial intelligence based on information available
on the platformโs project page and publicly accessible data. It is provided for
informational purposes only and does not constitute investment advice, financial
guidance, risk assessment, or project scoring. Platforms and project owners are not
involved in the creation, review, or endorsement of this content.
AI project overview
Condensed summary based on project data
<p><span style="font-size:28pt"><span style="font-family:"Times New Roman",serif">Biogenera S.p.A. — Crowdfunding Investor Memo</span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.</em></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Sector: </strong><em>Biotech — paediatric oncology, orphan drugs</em><strong> · Stage: </strong><em>Pre-revenue, entering first human trial (Phase I planned Q1 2027)</em><strong> · HQ: </strong><em>Bologna area (Alto Reno Terme / Ozzano dell'Emilia), Italy</em><strong> · Raise: </strong><em>€250K minimum – €5.0M maximum on CrowdFundMe; €469K raised at 26 Aug 2026</em></span></span></p>
<h1><span style="font-size:16pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">Snapshot</span></span></span></h1>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:627px">
<tbody>
<tr>
<td style="background-color:#f0f4f8; border-bottom:1px solid #999999; border-left:1px solid #999999; border-right:1px solid #999999; border-top:1px solid #999999; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">1 · Is the price fair? ๐ถ</span></strong></span></span></p>
</td>
<td style="background-color:#faeeda; border-bottom:1px solid #999999; border-left:none; border-right:1px solid #999999; border-top:1px solid #999999; vertical-align:top; width:433px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">3 / 5</span></strong><span style="color:black"> — Stretched but arguable. The €90m pre-money sits above the 2025 average for VC-priced biotech Series A rounds (≈ $79M, Qubit Capital) and below the $150–300M range recorded for Phase 1–2 biotechs (Baybridge Bio) — but those are institutional rounds with stronger investor rights, and Biogenera's price has been set by the company itself across successive crowd rounds (€70m in 2021, €80m in 2024).</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f0f4f8; border-bottom:1px solid #999999; border-left:1px solid #999999; border-right:1px solid #999999; border-top:none; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">2 · Can they reach an exit stage? โญ</span></strong></span></span></p>
</td>
<td style="background-color:#faece7; border-bottom:1px solid #999999; border-left:none; border-right:1px solid #999999; border-top:none; vertical-align:top; width:433px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE 58 / 100 — Average</span></strong><span style="color:black"> The drug is manufactured to clinical standard and its orphan status is independently confirmed; the biggest gap is money — €0.9m of cash at the end of 2025 against a yearly cash decrease of €1.9m, with the first patient still five months away.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f0f4f8; border-bottom:1px solid #999999; border-left:1px solid #999999; border-right:1px solid #999999; border-top:none; vertical-align:top; width:193px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">3 · If they do, what could it pay? ๐ฏ</span></strong></span></span></p>
</td>
<td style="background-color:#f0f4f8; border-bottom:1px solid #999999; border-left:none; border-right:1px solid #999999; border-top:none; vertical-align:top; width:433px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target 5–7x over 4–6 years</span></strong><span style="color:black"> (stage-standard for a company at this level of funding — the company gives no target of its own). If reached, illustratively <strong>1.5x–4x</strong> before fees and future dilution. Method: the disclosed post-money of €95m compared with the next-stage valuations the benchmarks record for biotechs entering or in early trials — $79M Series A average (Qubit Capital, 2026) and $150–400M Series B (Baybridge Bio) — treating dollars and euros as roughly equal for this illustration. The 5–7x target itself would need an equity value of roughly €478m–€668m, above the top of the next-stage valuations we could find on record. These figures do not include dilution from future fundraising rounds, which would reduce an early investor's share and actual returns — see the dilution section for how this works.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>How to read the score</strong></span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:627px">
<tbody>
<tr>
<td style="background-color:#d9ebc2; border-bottom:1px solid #999999; border-left:1px solid #999999; border-right:1px solid #999999; border-top:1px solid #999999; vertical-align:top; width:160px">
<p><span style="font-size:10pt">
โฆ
Equity crowdfunding
Real Estate Crowdfunding
